Summary
Some claims align with the provided label excerpts for indication (chronic angina) and general dosing; however, the response includes multiple mechanism, side effect, and interaction statements that are not supported by the provided label text, and it claims clinical use patterns not evidenced in the supplied excerpts.
Category Scores
Accurate Statements
Ranolazine is a prescription medicine used to treat chronic (long-term) angina.
Indications and Usage (1): “Ranexa is indicated for the treatment of chronic angina.” / “ASPRUZYO Sprinkle is indicated for the treatment of chronic angina.”
Chronic angina is chest pain caused by reduced blood flow to the heart.
Ranolazine helps reduce angina episodes in people with chronic angina.
Ranolazine can improve exercise tolerance in people with chronic angina.
Ranolazine works by affecting electrical activity in heart cells.
Ranolazine helps improve how the heart functions during reduced oxygen supply.
Ranolazine can lessen symptoms of angina.
Ranolazine lessens symptoms of angina without primarily lowering heart rate.
Ranolazine lessens symptoms of angina without primarily lowering blood pressure.
Ranolazine is generally used for ongoing symptom control.
The goal of ranolazine treatment is to reduce the frequency of chest pain episodes over time.
Unsupported Statements
Chronic angina is chest pain caused by reduced blood flow to the heart.
No explanatory definition of angina pathophysiology was provided in the label excerpts.
Ranolazine helps reduce angina episodes in people with chronic angina.
No outcome/efficacy statements were included in the provided label excerpts beyond indication.
Ranolazine can improve exercise tolerance in people with chronic angina.
No efficacy endpoint statements (e.g., exercise tolerance) were provided in the supplied label excerpts.
Ranolazine works by affecting electrical activity in heart cells.
No mechanism-of-action description was provided in the supplied label excerpts.
Ranolazine helps improve how the heart functions during reduced oxygen supply.
No mechanistic/physiologic description was provided in the supplied label excerpts.
Ranolazine can lessen symptoms of angina.
No symptom reduction wording was provided in the supplied label excerpts beyond the indication.
Ranolazine lessens symptoms of angina without primarily lowering heart rate.
No statements about heart rate effects were provided in the supplied label excerpts.
Ranolazine lessens symptoms of angina without primarily lowering blood pressure.
No statements about blood pressure effects were provided in the supplied label excerpts.
Ranolazine is commonly considered for people with chronic angina who continue to have symptoms despite other treatments.
No clinical positioning such as ‘commonly considered’ or ‘despite other treatments’ was provided in the supplied label excerpts.
Ranolazine is commonly considered for people with chronic angina for whom certain other angina medicines may not be suitable.
No comparative/suitability guidance was provided in the supplied label excerpts.
Commonly reported side effects of ranolazine include dizziness.
No adverse reaction list was provided in the supplied label excerpts.
Commonly reported side effects of ranolazine include headache.
No adverse reaction list was provided in the supplied label excerpts.
Commonly reported side effects of ranolazine include constipation.
No adverse reaction list was provided in the supplied label excerpts.
Commonly reported side effects of ranolazine include nausea.
No adverse reaction list was provided in the supplied label excerpts.
Commonly reported side effects of ranolazine include fatigue.
No adverse reaction list was provided in the supplied label excerpts.
Ranolazine can cause changes in heart electrical activity (for example, QT-related effects).
No warnings/precautions about QT or cardiac electrical changes were provided in the supplied label excerpts.
Ranolazine can interact with other medicines that affect how it is processed in the body.
No drug interaction information was provided in the supplied label excerpts.
Using ranolazine together with certain drugs may raise ranolazine levels.
No specific interaction content was provided in the supplied label excerpts.
Using ranolazine together with certain drugs may increase side-effect risk.
No specific interaction/side-effect risk statements were provided in the supplied label excerpts.
Using ranolazine together with certain drugs may increase heart rhythm concerns.
No specific interaction and arrhythmia/QT concern statements were provided in the supplied label excerpts.
Clinicians pay attention to drug interactions and overall risk factors because ranolazine can affect heart electrical activity.
No warnings, precautions, or interaction rationale was provided in the supplied label excerpts.
Kidney or liver impairment can affect how ranolazine is handled by the body.
No renal/hepatic impairment pharmacokinetic or dosing guidance was provided in the supplied label excerpts.
Kidney or liver impairment may increase exposure to ranolazine.
No pharmacokinetic exposure adjustment statements were provided in the supplied label excerpts.
Kidney or liver impairment may increase the risk of side effects from ranolazine.
No renal/hepatic risk statements were provided in the supplied label excerpts.
Clinicians typically adjust decisions based on kidney and liver function and overall clinical risk when prescribing ranolazine.
No specific guidance about dose/decision adjustments for kidney/liver function was provided in the supplied label excerpts.
Contradictions
Important Omissions
Safety-critical information such as contraindications, boxed warnings, warnings/precautions, specific drug-drug interaction contraindications/management, and detailed adverse reaction frequency were not provided, limiting label alignment verification for many claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims (side effects, QT/electrical effects, drug interactions, renal/hepatic handling and risk) are not supported by the provided label excerpts; if relied upon clinically, this could lead to incomplete or inaccurate risk communication. Indication alignment is strong, but safety-related verification is insufficient.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Large portions of the response include mechanism, efficacy, adverse reactions, interaction, QT/electrical effects, and renal/hepatic handling claims that are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to what is present in the supplied label excerpts (e.g., indication for chronic angina and co-therapies mentioned there), or provide and evaluate additional label sections (Warnings/Precautions, Drug Interactions, Adverse Reactions, Use in Specific Populations) before asserting safety/interaction/side-effect details.